Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines.
This is the first report enumerating a superb antiproliferative effect of both sulindac and exisulind on hepatocellular cancer cell lines. The growth inhibition and cytotoxicity of sulindac in human hepatocellular carcinoma cell lines HepG2, Huh-7, and KYN-2 were investigated by studying cell growth, cell cycle distribution, and induction of apoptosis. In the presence of sulindac, there was a marked time- and dose-dependent decrease in cell proliferation and viability. Also, exisulind exhibited a similar growth-inhibitory effect on the KYN-2 cell line. The findings of this study suggest that sulindac exhibits a growth-inhibitory effect on human hepatocellular carcinoma cell lines; therefore, these drugs might serve as an effective tool for hepatocellular carcinoma chemoprevention.
Rahman
M A
MA
Second Department of Surgery, Shimane Medical University, Izumo, Japan. rahman@shimane-med.ac.jp
Dhar
D K
DK
Masunaga
R
R
Yamanoi
A
A
Kohno
H
H
Nagasue
N
N
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000235:genetics / Q000473:pathology* / Q000517:prevention & control; D002455:Cell Division / Q000187:drug effects; D051546:Cyclooxygenase 2; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D007399:Interphase / Q000187:drug effects; D007527:Isoenzymes / Q000235:genetics; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology* / Q000517:prevention & control; D008565:Membrane Proteins; D009336:Necrosis; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D013467:Sulindac / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D014407:Tumor Cells, Cultured
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D007527:Isoenzymes; D008565:Membrane Proteins; D012333:RNA, Messenger; D013467:Sulindac; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C025463:sulindac sulfone